Beyond air announces $20.6 million private placement offering priced at-the-market under nasdaq rules

– financing strengthens balance sheet and is expected to provide sufficient cash runway through june 2026 –       – retiring $17.5 million in avenue capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through june 2026 – – avenue capital, current insiders, and select group of healthcare-focused investment funds participated in the equity offering – garden city, n.y., sept. 27, 2024 (globe newswire) --  beyond air, inc. (nasdaq: xair) (“beyond air” or the “company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (no) to improve the lives of patients, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors, as well as company insiders.
NDAQ Ratings Summary
NDAQ Quant Ranking